China’s NMPA okays maribavir for post-transplant cytomegalovirus

Stem cell transplant

Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease.

It has been licensed by the National Medical Products Administration (NMPA) in cases where the infection is resistant to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.

CMV is one of the most common infections experienced by transplant patients, with an estimated incidence rate of 16%-56% in SOT and 30%-80% in HSCT recipients.

“The approval of Livtencity by the NMPA of China recognises the critical need for post-transplant care and that CMV infection, when not successfully treated, can pose serious challenges to transplant recipients that can lead to complications such as increased organ rejection and hospitalisation rates,” said Ramona Sequeira, President, Global Portfolio Division, Takeda.

“This approval will help redefine the CMV treatment landscape for transplant patients in China and is a positive step forward toward addressing an unmet need for this community.”

Phase III SOLSTICE trial and previous approvals

The NMPA approval is based on the results of the Phase III SOLSTICE trial, which evaluated the safety and efficacy of maribavir versus conventional antiviral therapies for the treatment of patients with CMV infection/disease refractory to prior therapies.

In the SOLSTICE trial, Livtencity was superior to conventional therapies at week eight for the primary endpoint of confirmed CMV viremia clearancea in post-transplant adults with refractory CMV infection.

Livtencity is already approved for post-transplant CMV refractory to prior therapies in twelve other territories including the United States, Canada, Australia and the European Union.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free